Core Viewpoint - Moderna is expanding its U.S. manufacturing capabilities by onshoring Drug Product manufacturing to its existing Moderna Technology Center in Norwood, Massachusetts, marking a significant step in strengthening its domestic mRNA production network [1] Group 1: Investment and Job Creation - The expansion involves an investment of more than $140 million, which is expected to create hundreds of highly skilled biomanufacturing jobs [1] Group 2: Manufacturing Capabilities - With this strategic onshoring, Moderna will now operate full end-to-end manufacturing for its mRNA medicines in the U.S., supporting both commercial and clinical supply [1] - This milestone reinforces the company's commitment to domestic mRNA production [1]